Advertisement

Genetic Aberrations and Molecular Pathways in Head and Neck Cancer

  • Luis MonteiroEmail author
  • Saman Warnakulasuriya
Chapter

Abstract

In this chapter, we provide a comprehensive overview of common genetic aberrations so far discovered in head and neck cancer. We discuss how these genetic alterations may affect protein structure and function. We also highlight the latest discoveries in signalling pathways affected as a result of these genetic aberrations. A better understanding of these mechanisms underlying cancer formation, progression and resistance to therapy leads us to the next five chapters that discuss each of the key driver mutations and tumour suppressors that are lost in head and neck cancer.

Keywords

EGFREpidermal Growth Factor Receptor Oral Cancer Vascular Endothelial Growth Factor Receptor EGFREpidermal Growth Factor Receptor Mutation EGFREpidermal Growth Factor Receptor Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333(6046):1154–1157Google Scholar
  2. Bilde A, Dabelsteen E, Therkildsen MH, Dabelsteen S (2009) Molecular markers in the surgical margin of oral carcinomas. J Oral Pathol Med 38(1):72–78Google Scholar
  3. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578Google Scholar
  4. Chung CH, Parker JS, Karaca G, Wu JY, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zonation A, Yin XY, Shockley WW, Weissler MC, Dressler LG, Shores CG, Yarbrough WG, Perou CM (2004) Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5(5):489–500Google Scholar
  5. Forastiere A, Koch W, Trotti A, Sidransky D (2001) Head and neck cancer. N Engl J Med 345(26):1890–1900Google Scholar
  6. Grandis JR, Tweardy DJ (1993) Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53:3579–3584Google Scholar
  7. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90(11):824–832Google Scholar
  8. Grandis JR, Zeng Q, Drenning SD (2000) Epidermal growth factor receptor-mediated Stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope 110:868–874Google Scholar
  9. Hahn WC, Weinberg RA (2002) Rules for making human tumour cells. N Engl J Med 347:1593–1603Google Scholar
  10. Hijioka H, Setoguchi T, Miyawaki A, Gao H, Ishida T, Komiya S, Nakamura N (2010) Upregulation of Notch pathway molecules in oral squamous cell carcinoma. Int J Oncol 36(4):817–822Google Scholar
  11. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2(4):289–300Google Scholar
  12. Hsu HW, Wall NR, Hsueh CT, Kim S, Ferris RL, Chen CS, Mirshahidi S (2014) Combination antiangiogenic therapy and radiation in head and neck cancers. Oral Oncol 50(1):19–26Google Scholar
  13. Izumchenko E, Sun K, Jones S, Brait M, Agrawal N, Koch W, McCord CL, Riley DR, Angiuoli SV, Velculescu VE, Jiang WW, Sidransky D (2015) Notch1 mutations are drivers of oral tumorigenesis. Cancer Prev Res (Phila) 8:277–286Google Scholar
  14. Kayamori K, Katsube K, Sakamoto K, Ohyama Y, Hirai H, Yukimori A, Ohata Y, Akashi T, Saitoh M, Harada K, Harada H, Yamaguchi A (2016) NOTCH3 is induced in cancer-associated fibroblasts and promotes angiogenesis in oral squamous cell carcinoma. PLoS One 11(4):e0154112Google Scholar
  15. Khalil MY, Grandis JR, Shin DM (2003) Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev Anticancer Ther 3:367–380Google Scholar
  16. Khan Z, Bisen PS (2013) Oncoapoptotic signaling and deregulated target genes in cancers: special reference to oral cancer. Biochim Biophys Acta 1836(1):123–145Google Scholar
  17. Lane DP (1992) Cancer. P53, guardian of the genome. Nature 358:15–16Google Scholar
  18. Lippert BM, Knauer SK, Fetz V, Mann W, Stauber RH (2007) Dynamic survivin in head and neck cancer: molecular mechanism and therapeutic potential. Int J Cancer 121(6):1169–1174Google Scholar
  19. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, Hilbe W, Schwentner I, Sprinzl GM et al (2006) Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 42:109–111Google Scholar
  20. Mao L, Hong WK, Papadimitrakopoulou VA (2004) Focus on head and neck cancer. Cancer Cell 5(4):311–316Google Scholar
  21. Marques AE, Elias ST, Porporatti AL, Castilho RM, Squarize CH, De Luca Canto G, Guerra EN (2016) mTOR pathway protein immunoexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta-analysis. J Oral Pathol Med 45(5):319–328Google Scholar
  22. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS (2009) Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 45(4–5):324–334CrossRefPubMedGoogle Scholar
  23. Monteiro LS, Diniz-Freitas M, Garcia-Caballero T, Warnakulasuriya S, Forteza J, Fraga M (2012) Combined cytoplasmic and membranous EGFR and p53 overexpression is a poor prognostic marker in early stage oral squamous cell carcinoma. J Oral Pathol Med 41(7):559–567PubMedGoogle Scholar
  24. Monteiro L, Ricardo S, Delgado M, Garcez F, do Amaral B, Lopes C (2014) Phosphorylated EGFR at tyrosine 1173 correlates with poor prognosis in oral squamous cell carcinomas. Oral Dis 20(2):178–185CrossRefPubMedGoogle Scholar
  25. Murugan AK, Munirajan AK, Tsuchida N (2012) Ras oncogenes in oral cancer: the past 20 years. Oral Oncol 48(5):383–392CrossRefPubMedGoogle Scholar
  26. Neuchrist C, Erovic BM, Handisurya A, Steiner GE, Rockwell P, Gedlicka C, Burian M (2001) Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 111(10):1834–1841CrossRefPubMedGoogle Scholar
  27. O-charoenrat P, Rhys-Evans PH, Archer DJ, Eccles SA (2002) C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol 38:73–80CrossRefPubMedGoogle Scholar
  28. Oliveira LR, Ribeiro-Silva A, Costa JP, Simões AL, Matteo MA, Zucoloto S (2008) Prognostic factors and survival analysis in a sample of oral squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106(5):685–695CrossRefPubMedGoogle Scholar
  29. Partridge M, Costea DE, Huang X (2007) The changing face of p53 in head and neck cancer. Int J Oral Maxillofac Surg 36(12):1123–1138CrossRefPubMedGoogle Scholar
  30. Sacco AG, Worden FP (2016) Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. Onco Targets Ther 9:1927–1943PubMedPubMedCentralGoogle Scholar
  31. Saranath D, Chang SE, Bhoite LT, Panchal RG, Kerr IB, Mehta AR, Johnson NW, Deo MG (1991) High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 63(4):573–578CrossRefPubMedPubMedCentralGoogle Scholar
  32. Sauer T, Guren MG, Noren T, Dueland S (2005) Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy? Histopathology 47:560–564CrossRefPubMedGoogle Scholar
  33. Simpson DR, Mell LK, Cohen EE (2015) Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. Oral Oncol 51(4):291–298CrossRefPubMedGoogle Scholar
  34. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL et al (2006) Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12:5064–5073CrossRefPubMedGoogle Scholar
  35. Song X, Xia R, Li J, Long Z, Ren H, Chen W, Mao L (2014) Common and complex Notch1 mutations in Chinese oral squamous cell carcinoma. Clin Cancer Res 20:701–710CrossRefPubMedGoogle Scholar
  36. Sun W, Califano JA (2014) Sequencing the head and neck cancer genome: implications for therapy. Ann N Y Acad Sci 1333:33–42CrossRefPubMedPubMedCentralGoogle Scholar
  37. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD et al (2007) Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25:2164–2170Google Scholar
  38. Vassilakopoulou M, Psyrri A, Argiris A (2015) Targeting angiogenesis in head and neck cancer. Oral Oncol 51(5):409–415Google Scholar
  39. Venook AP (2005) Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 103:2435–2446Google Scholar
  40. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J (2008) Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 112(12):2710–2719Google Scholar
  41. Warnakulasuriya S, Chang SE, Johnson NW (1992) Point mutations in the Ha-ras oncogene are detectable in formalin-fixed tissues of oral squamous cell carcinomas, but are infrequent in British cases. J Oral Pathol Med 21:225–9Google Scholar
  42. Warnakulasuriya S (2000) Lack of molecular markers to predict malignant potential of oral precancer. J Pathol 190(4):407–409Google Scholar
  43. Xu K, Liu P, Wei W (2014) mTOR signaling in tumorigenesis. Biochim Biophys Acta 1846(2):638–654Google Scholar
  44. Yap LF, Lee D, Khairuddin A, Pairan MF, Puspita B, Siar CH, Paterson IC (2015) The opposing roles of NOTCH signalling in head and neck cancer: a mini review. Oral Dis 21(7):850–857Google Scholar
  45. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137Google Scholar
  46. Yoshida R, Nagata M, Nakayama H, Niimori-Kita K, Hassan W, Tanaka T, Shinohara M, Ito T (2013) The pathological significance of Notch1 in oral squamous cell carcinoma. Lab Invest 93(10):1068–1081Google Scholar
  47. Zang J, Li C, Zhao LN, Shi M, Zhou YC, Wang JH, Li X (2013) Prognostic value of vascular endothelial growth factor in patients with head and neck cancer: a meta-analysis. Head Neck 35(10):1507–1514Google Scholar
  48. Zhang JP, Qin HY, Wang L, Liang L, Zhao XC, Cai WX, Wei YN, Wang CM, Han H (2011) Overexpression of notch ligand Dll1 in B16 melanoma cells leads to reduced tumor growth due to attenuated vascularization. Cancer Lett 309:220–227CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  1. 1.Department of Medicine and Oral Surgery, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde (IINFACTS), Instituto Universitário de Ciências da Saúde (IUCS)CESPUGandraPortugal
  2. 2.Oral Medicine and Experimental PathologyKing’s College LondonLondonUK

Personalised recommendations